We are live on ! Find out more
LJPC

La Jolla Pharmaceutical Company

Delisted

LJPC was delisted on the 19th of August, 2022.

71 hedge funds and large institutions have $382M invested in La Jolla Pharmaceutical Company in 2016 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 25 increasing their positions, 21 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

839% more call options, than puts

Call options by funds: $7.65M | Put options by funds: $815K

100% more funds holding in top 10

Funds holding in top 10: 24 (+2)

49% more capital invested

Capital invested by funds: $256M → $382M (+$126M)

19% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 21

3% less funds holding

Funds holding: 7371 (-2)

20% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 10

Holders
71
Holders Change
-2
Holders Change %
-2.74%
% of All Funds
1.89%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.11%
New
8
Increased
25
Reduced
21
Closed
10
Calls
$7.65M
Puts
$815K
Net Calls
+$6.84M
Net Calls Change
+$4.49M
Name Holding Trade Value Shares
Change
Change in
Stake
Manulife (Manufacturers Life Insurance)
51
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$236K +$4.58K +243 +3%
NFA
52
Nationwide Fund Advisors
Ohio
$218K
State Board of Administration of Florida Retirement System
53
State Board of Administration of Florida Retirement System
Florida
$216K +$171K +9,080 New
CG
54
Cutler Group
California
$195K +$28.6K +1,516 +23%
AIG
55
American International Group
New York
$191K +$226 +12 +0.1%
BA
56
BlackRock Advisors
Delaware
$172K +$9.72K +516 +8%
BG
57
BlackRock Group
United Kingdom
$89K +$4.63K +246 +7%
Canada Life
58
Canada Life
Manitoba, Canada
$63K
Legal & General Group
59
Legal & General Group
United Kingdom
$48K
Group One Trading
60
Group One Trading
Illinois
$43K -$180K -9,558 -84%
PCM
61
Prelude Capital Management
New York
$43K -$23.4K -1,240 -41%
BlackRock
62
BlackRock
New York
$29K +$3.69K +196 +19%
CAL
63
Capital Advisors Ltd
Ohio
$24K +$18.8K +1,000 New
BNP Paribas Financial Markets
64
BNP Paribas Financial Markets
France
$23.3K +$8.27K +439 +81%
Royal Bank of Canada
65
Royal Bank of Canada
Ontario, Canada
$20K -$4.65K -247 -22%
TRCT
66
Tower Research Capital (TRC)
New York
$17K -$30.1K -1,595 -69%
Citigroup
67
Citigroup
New York
$12K
Barclays
68
Barclays
United Kingdom
$8K +$5.37K +285 +491%
IA
69
IFP Advisors
Florida
$4K
WA
70
WFG Advisors
Texas
$3K
TCIM
71
TIAA CREF Investment Management
New York
$1.02K -$3.96K -210 -0.5%
ACA
72
Avoro Capital Advisors
New York
-$1.12M -70,000 Closed
BGA
73
Belmont Global Advisors
Texas
-$960K -60,000 Closed
LCM
74
Landscape Capital Management
New Jersey
-$852K -53,254 Closed
GCP
75
GSA Capital Partners
United Kingdom
-$718K -44,900 Closed

LJPC Hedge Fund Activity: Q3 2016 in Review

71 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q3 2016, worth a combined $382M — up 49% from $256M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of LJPC and 8 opened new positions — a net loss of 2 holders — while 21 trimmed existing stakes and 25 added.

The largest buyer was PointState Capital, opening a new position worth an estimated $3.77M. The largest seller was Granahan Investment Management, cutting an estimated $2.78M.

  • 71 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q3 2016, down from 73 in Q2 2016.
  • Funds reported $382M of La Jolla Pharmaceutical Company stock for Q3 2016, up 49% quarter-over-quarter.
  • 8 funds opened new La Jolla Pharmaceutical Company positions in Q3 2016 and 10 closed out, a net change of -2 holders.
  • The largest La Jolla Pharmaceutical Company buyer in Q3 2016 was PointState Capital, an estimated $3.77M added.
  • The largest La Jolla Pharmaceutical Company seller in Q3 2016 was Granahan Investment Management, an estimated $2.78M sold.

Based on aggregated 13F filings for Q3 2016.